Spero Science joined the 8th CIMES (ABIMO, FIESP) and the First Meeting of the EMBRAPII USP Network at HC-FMUSP. Why it matters for health-tech co-development.

A guide for investors, venture funds, pharmaceutical and medical-device companies, hospitals and research institutions who want to work with Spero Science Innovation — what we are building, what stage each platform is at, and the ways to collaborate.

What "translational" really means at Spero Science — the São Paulo ecosystem of USP, HC-FMUSP and Hospital Sírio-Libanês, the funding and innovation partners behind it, the ANVISA pathway for advanced therapies, and why Brazil is a strategic base for musculoskeletal regenerative medicine.

Why the next generation of orthopedic AI will not read images alone — how Spero Science AI integrates MRI and X-ray, genetic profiles and patient-reported outcomes to predict who will progress, who will respond to treatment and who needs surgery.

A plain-language reading of the 2024 meta-analysis of 25 randomized trials on mesenchymal stromal cell therapy for knee osteoarthritis, led by Spero Science's founders — what works, what is uncertain, and why GMP manufacturing and tissue engineering are the next step.

Why articular cartilage does not heal on its own, what "chondroinduction" means, and how an injectable chondroinductive molecule could treat osteoarthritis and focal cartilage lesions without open surgery — the science behind Spero Science's lead platform.